UroGen Pharma Ltd

NASDAQ:URGN  
7.94
-0.37 (-4.45%)
Earnings Announcements

Urogen Pharma Reports Third Quarter Results

Published: 11/10/2022 13:17 GMT
UroGen Pharma Ltd (URGN) - Q3 Loss per Share $1.13.
Urogen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments.
Q3 2022 Net Product Revenue of Jelmyto $16.1 Million Versus $11.4 Million Q3 of 2021.
Urogen Pharma - Full Enrollment of Envision Phase 3 Trial With Ugn-102 in Lg-ir-nmibc Expected As Soon As End of November 2022.
Q3 Earnings per Share View $-1.16 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $19.1 Million
Adjusted EPS is expected to be -$1.05

Next Quarter Revenue Guidance is expected to be $20.3 Million
Next Quarter EPS Guidance is expected to be -$1.00

More details on our Analysts Page.